Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer.
Maximal androgen blockade therapy is the standard endocrine treatment for advanced prostate cancer. We report here an unusual case of interstitial pneumonitis induced by bicalutamide and/or leuprorelin acetate treatment for metastatic prostate cancer.
Shioi
Koichi
K
Department of Urology, Yokosuka Hokubu Kyosai Hospital, Funakoshi, Yokosuka, Kanagawa, Japan.
Yoshida
Minoru
M
Sakai
Naoki
N
D000368:Aged; D000813:Anilides / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014105:Tosyl Compounds; D016896:Treatment Outcome
D000813:Anilides; D005938:Glucocorticoids; D009570:Nitriles; D014105:Tosyl Compounds; D008776:Methylprednisolone Hemisuccinate; C053541:bicalutamide; D016729:Leuprolide